nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—FMO3—metabolic syndrome X	0.66	0.917	CbGaD
Vandetanib—ALB—metabolic syndrome X	0.0599	0.0832	CbGaD
Vandetanib—RET—autonomic nervous system—metabolic syndrome X	0.00469	0.0508	CbGeAlD
Vandetanib—Viral diarrhoea—Metformin—metabolic syndrome X	0.00381	0.145	CcSEcCtD
Vandetanib—Erlotinib—NR1I2—metabolic syndrome X	0.00278	0.781	CrCbGaD
Vandetanib—FLT4—endothelium—metabolic syndrome X	0.00254	0.0276	CbGeAlD
Vandetanib—RIPK2—endothelium—metabolic syndrome X	0.00253	0.0274	CbGeAlD
Vandetanib—TEK—artery—metabolic syndrome X	0.00242	0.0262	CbGeAlD
Vandetanib—FLT4—blood vessel—metabolic syndrome X	0.00234	0.0254	CbGeAlD
Vandetanib—RIPK2—blood vessel—metabolic syndrome X	0.00233	0.0253	CbGeAlD
Vandetanib—SRC—artery—metabolic syndrome X	0.00215	0.0233	CbGeAlD
Vandetanib—TEK—endothelium—metabolic syndrome X	0.00204	0.0222	CbGeAlD
Vandetanib—KDR—artery—metabolic syndrome X	0.00198	0.0214	CbGeAlD
Vandetanib—TEK—blood vessel—metabolic syndrome X	0.00189	0.0204	CbGeAlD
Vandetanib—SRC—endothelium—metabolic syndrome X	0.00182	0.0197	CbGeAlD
Vandetanib—SRC—blood vessel—metabolic syndrome X	0.00168	0.0182	CbGeAlD
Vandetanib—KDR—endothelium—metabolic syndrome X	0.00167	0.0181	CbGeAlD
Vandetanib—KDR—blood vessel—metabolic syndrome X	0.00154	0.0167	CbGeAlD
Vandetanib—Nail disorder—Metformin—metabolic syndrome X	0.00153	0.0583	CcSEcCtD
Vandetanib—PDGFRB—blood vessel—metabolic syndrome X	0.00133	0.0145	CbGeAlD
Vandetanib—Fungal infection—Metformin—metabolic syndrome X	0.00129	0.049	CcSEcCtD
Vandetanib—BMPR1B—adipose tissue—metabolic syndrome X	0.00117	0.0127	CbGeAlD
Vandetanib—FLT3—cardiovascular system—metabolic syndrome X	0.00115	0.0125	CbGeAlD
Vandetanib—FLT4—cardiovascular system—metabolic syndrome X	0.00105	0.0113	CbGeAlD
Vandetanib—RIPK2—cardiovascular system—metabolic syndrome X	0.00104	0.0113	CbGeAlD
Vandetanib—FMO1—kidney—metabolic syndrome X	0.00101	0.0109	CbGeAlD
Vandetanib—STK35—adipose tissue—metabolic syndrome X	0.000995	0.0108	CbGeAlD
Vandetanib—ERBB3—kidney—metabolic syndrome X	0.000974	0.0106	CbGeAlD
Vandetanib—ABL2—adipose tissue—metabolic syndrome X	0.00097	0.0105	CbGeAlD
Vandetanib—EGFR—adipose tissue—metabolic syndrome X	0.000946	0.0103	CbGeAlD
Vandetanib—MKNK1—cardiovascular system—metabolic syndrome X	0.000935	0.0101	CbGeAlD
Vandetanib—FGR—cardiovascular system—metabolic syndrome X	0.000923	0.01	CbGeAlD
Vandetanib—FLT4—adipose tissue—metabolic syndrome X	0.000922	0.01	CbGeAlD
Vandetanib—AXL—cardiovascular system—metabolic syndrome X	0.00092	0.00997	CbGeAlD
Vandetanib—RIPK2—adipose tissue—metabolic syndrome X	0.000917	0.00995	CbGeAlD
Vandetanib—VEGFA—adipose tissue—metabolic syndrome X	0.000915	0.00992	CbGeAlD
Vandetanib—FMO1—adipose tissue—metabolic syndrome X	0.00091	0.00987	CbGeAlD
Vandetanib—RET—kidney—metabolic syndrome X	0.000904	0.0098	CbGeAlD
Vandetanib—IRAK4—adipose tissue—metabolic syndrome X	0.000896	0.00971	CbGeAlD
Vandetanib—ERBB3—adipose tissue—metabolic syndrome X	0.000878	0.00952	CbGeAlD
Vandetanib—FYN—cardiovascular system—metabolic syndrome X	0.000861	0.00933	CbGeAlD
Vandetanib—FYN—kidney—metabolic syndrome X	0.000842	0.00913	CbGeAlD
Vandetanib—TEK—cardiovascular system—metabolic syndrome X	0.000841	0.00912	CbGeAlD
Vandetanib—LYN—liver—metabolic syndrome X	0.000833	0.00903	CbGeAlD
Vandetanib—MKNK1—adipose tissue—metabolic syndrome X	0.000824	0.00894	CbGeAlD
Vandetanib—TEK—kidney—metabolic syndrome X	0.000823	0.00892	CbGeAlD
Vandetanib—FGR—adipose tissue—metabolic syndrome X	0.000814	0.00883	CbGeAlD
Vandetanib—LCK—adipose tissue—metabolic syndrome X	0.000814	0.00883	CbGeAlD
Vandetanib—AXL—adipose tissue—metabolic syndrome X	0.000811	0.00879	CbGeAlD
Vandetanib—FMO3—adipose tissue—metabolic syndrome X	0.000786	0.00853	CbGeAlD
Vandetanib—SLK—adipose tissue—metabolic syndrome X	0.000781	0.00846	CbGeAlD
Vandetanib—STK10—cardiovascular system—metabolic syndrome X	0.00077	0.00835	CbGeAlD
Vandetanib—YES1—kidney—metabolic syndrome X	0.00076	0.00824	CbGeAlD
Vandetanib—FYN—adipose tissue—metabolic syndrome X	0.000759	0.00823	CbGeAlD
Vandetanib—STK10—kidney—metabolic syndrome X	0.000753	0.00817	CbGeAlD
Vandetanib—SRC—cardiovascular system—metabolic syndrome X	0.000747	0.0081	CbGeAlD
Vandetanib—TEK—adipose tissue—metabolic syndrome X	0.000742	0.00804	CbGeAlD
Vandetanib—MAP4K5—adipose tissue—metabolic syndrome X	0.000742	0.00804	CbGeAlD
Vandetanib—Hypoglycaemia—Metformin—metabolic syndrome X	0.000741	0.0281	CcSEcCtD
Vandetanib—Lethargy—Metformin—metabolic syndrome X	0.000737	0.028	CcSEcCtD
Vandetanib—SRC—kidney—metabolic syndrome X	0.000731	0.00793	CbGeAlD
Vandetanib—FLT3—liver—metabolic syndrome X	0.000712	0.00772	CbGeAlD
Vandetanib—EPHB6—adipose tissue—metabolic syndrome X	0.000709	0.00769	CbGeAlD
Vandetanib—STK35—liver—metabolic syndrome X	0.000698	0.00756	CbGeAlD
Vandetanib—MAP2K5—cardiovascular system—metabolic syndrome X	0.000688	0.00745	CbGeAlD
Vandetanib—KDR—cardiovascular system—metabolic syndrome X	0.000688	0.00745	CbGeAlD
Vandetanib—YES1—adipose tissue—metabolic syndrome X	0.000685	0.00743	CbGeAlD
Vandetanib—ABL2—liver—metabolic syndrome X	0.00068	0.00737	CbGeAlD
Vandetanib—STK10—adipose tissue—metabolic syndrome X	0.000679	0.00736	CbGeAlD
Vandetanib—KDR—kidney—metabolic syndrome X	0.000673	0.00729	CbGeAlD
Vandetanib—Dehydration—Metformin—metabolic syndrome X	0.000672	0.0255	CcSEcCtD
Vandetanib—EGFR—liver—metabolic syndrome X	0.000664	0.00719	CbGeAlD
Vandetanib—SRC—adipose tissue—metabolic syndrome X	0.000659	0.00714	CbGeAlD
Vandetanib—FLT4—liver—metabolic syndrome X	0.000647	0.00701	CbGeAlD
Vandetanib—Nasopharyngitis—Metformin—metabolic syndrome X	0.000646	0.0245	CcSEcCtD
Vandetanib—RIPK2—liver—metabolic syndrome X	0.000643	0.00697	CbGeAlD
Vandetanib—VEGFA—liver—metabolic syndrome X	0.000642	0.00696	CbGeAlD
Vandetanib—FMO1—liver—metabolic syndrome X	0.000638	0.00692	CbGeAlD
Vandetanib—IRAK4—liver—metabolic syndrome X	0.000628	0.00681	CbGeAlD
Vandetanib—Influenza—Metformin—metabolic syndrome X	0.000625	0.0237	CcSEcCtD
Vandetanib—ERBB3—liver—metabolic syndrome X	0.000616	0.00668	CbGeAlD
Vandetanib—Pancreatitis—Metformin—metabolic syndrome X	0.000612	0.0233	CcSEcCtD
Vandetanib—KDR—adipose tissue—metabolic syndrome X	0.000606	0.00657	CbGeAlD
Vandetanib—MAP2K5—adipose tissue—metabolic syndrome X	0.000606	0.00657	CbGeAlD
Vandetanib—PDGFRB—cardiovascular system—metabolic syndrome X	0.000595	0.00645	CbGeAlD
Vandetanib—Neutropenia—Metformin—metabolic syndrome X	0.000584	0.0222	CcSEcCtD
Vandetanib—PDGFRB—kidney—metabolic syndrome X	0.000582	0.00631	CbGeAlD
Vandetanib—Upper respiratory tract infection—Metformin—metabolic syndrome X	0.000581	0.0221	CcSEcCtD
Vandetanib—MKNK1—liver—metabolic syndrome X	0.000578	0.00627	CbGeAlD
Vandetanib—LCK—liver—metabolic syndrome X	0.000571	0.00619	CbGeAlD
Vandetanib—FGR—liver—metabolic syndrome X	0.000571	0.00619	CbGeAlD
Vandetanib—AXL—liver—metabolic syndrome X	0.000569	0.00617	CbGeAlD
Vandetanib—Infestation NOS—Metformin—metabolic syndrome X	0.000557	0.0212	CcSEcCtD
Vandetanib—Infestation—Metformin—metabolic syndrome X	0.000557	0.0212	CcSEcCtD
Vandetanib—FMO3—liver—metabolic syndrome X	0.000552	0.00598	CbGeAlD
Vandetanib—SLK—liver—metabolic syndrome X	0.000548	0.00594	CbGeAlD
Vandetanib—FYN—liver—metabolic syndrome X	0.000532	0.00577	CbGeAlD
Vandetanib—ABL1—cardiovascular system—metabolic syndrome X	0.00053	0.00575	CbGeAlD
Vandetanib—Hepatobiliary disease—Metformin—metabolic syndrome X	0.000527	0.02	CcSEcCtD
Vandetanib—PDGFRB—adipose tissue—metabolic syndrome X	0.000525	0.00569	CbGeAlD
Vandetanib—MAP4K5—liver—metabolic syndrome X	0.00052	0.00564	CbGeAlD
Vandetanib—TEK—liver—metabolic syndrome X	0.00052	0.00564	CbGeAlD
Vandetanib—ABL1—kidney—metabolic syndrome X	0.000519	0.00563	CbGeAlD
Vandetanib—Bradycardia—Metformin—metabolic syndrome X	0.000509	0.0193	CcSEcCtD
Vandetanib—YES1—liver—metabolic syndrome X	0.00048	0.00521	CbGeAlD
Vandetanib—Erlotinib—ALB—metabolic syndrome X	0.00048	0.135	CrCbGaD
Vandetanib—STK10—liver—metabolic syndrome X	0.000476	0.00516	CbGeAlD
Vandetanib—ABL1—adipose tissue—metabolic syndrome X	0.000468	0.00507	CbGeAlD
Vandetanib—Eye disorder—Metformin—metabolic syndrome X	0.000467	0.0177	CcSEcCtD
Vandetanib—Cardiac disorder—Metformin—metabolic syndrome X	0.000464	0.0176	CcSEcCtD
Vandetanib—SRC—liver—metabolic syndrome X	0.000462	0.00501	CbGeAlD
Vandetanib—Angiopathy—Metformin—metabolic syndrome X	0.000454	0.0172	CcSEcCtD
Vandetanib—Mediastinal disorder—Metformin—metabolic syndrome X	0.000451	0.0171	CcSEcCtD
Vandetanib—Malnutrition—Metformin—metabolic syndrome X	0.000435	0.0165	CcSEcCtD
Vandetanib—Dysgeusia—Metformin—metabolic syndrome X	0.000426	0.0162	CcSEcCtD
Vandetanib—KDR—liver—metabolic syndrome X	0.000425	0.00461	CbGeAlD
Vandetanib—MAP2K5—liver—metabolic syndrome X	0.000425	0.00461	CbGeAlD
Vandetanib—Muscle spasms—Metformin—metabolic syndrome X	0.000418	0.0159	CcSEcCtD
Vandetanib—Vision blurred—Metformin—metabolic syndrome X	0.00041	0.0156	CcSEcCtD
Vandetanib—Tremor—Metformin—metabolic syndrome X	0.000408	0.0155	CcSEcCtD
Vandetanib—Loss of consciousness—Metformin—metabolic syndrome X	0.000383	0.0145	CcSEcCtD
Vandetanib—Hypertension—Metformin—metabolic syndrome X	0.000376	0.0143	CcSEcCtD
Vandetanib—Chest pain—Metformin—metabolic syndrome X	0.000371	0.0141	CcSEcCtD
Vandetanib—PDGFRB—liver—metabolic syndrome X	0.000368	0.00399	CbGeAlD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Metformin—metabolic syndrome X	0.000368	0.014	CcSEcCtD
Vandetanib—ABCC1—adipose tissue—metabolic syndrome X	0.000356	0.00386	CbGeAlD
Vandetanib—Oedema—Metformin—metabolic syndrome X	0.000355	0.0135	CcSEcCtD
Vandetanib—Infection—Metformin—metabolic syndrome X	0.000353	0.0134	CcSEcCtD
Vandetanib—Nervous system disorder—Metformin—metabolic syndrome X	0.000348	0.0132	CcSEcCtD
Vandetanib—Thrombocytopenia—Metformin—metabolic syndrome X	0.000348	0.0132	CcSEcCtD
Vandetanib—ORM1—liver—metabolic syndrome X	0.000345	0.00374	CbGeAlD
Vandetanib—Skin disorder—Metformin—metabolic syndrome X	0.000345	0.0131	CcSEcCtD
Vandetanib—ABL1—liver—metabolic syndrome X	0.000328	0.00356	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.000324	0.0123	CcSEcCtD
Vandetanib—Paraesthesia—Metformin—metabolic syndrome X	0.000319	0.0121	CcSEcCtD
Vandetanib—Dyspnoea—Metformin—metabolic syndrome X	0.000317	0.012	CcSEcCtD
Vandetanib—Dyspepsia—Metformin—metabolic syndrome X	0.000313	0.0119	CcSEcCtD
Vandetanib—Decreased appetite—Metformin—metabolic syndrome X	0.000309	0.0117	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.000307	0.0116	CcSEcCtD
Vandetanib—Fatigue—Metformin—metabolic syndrome X	0.000306	0.0116	CcSEcCtD
Vandetanib—Constipation—Metformin—metabolic syndrome X	0.000304	0.0115	CcSEcCtD
Vandetanib—ALB—liver—metabolic syndrome X	0.000303	0.00328	CbGeAlD
Vandetanib—Gefitinib—ALB—metabolic syndrome X	0.0003	0.0844	CrCbGaD
Vandetanib—ABCG2—adipose tissue—metabolic syndrome X	0.000295	0.0032	CbGeAlD
Vandetanib—Gastrointestinal pain—Metformin—metabolic syndrome X	0.00029	0.011	CcSEcCtD
Vandetanib—Abdominal pain—Metformin—metabolic syndrome X	0.000281	0.0107	CcSEcCtD
Vandetanib—Asthenia—Metformin—metabolic syndrome X	0.000255	0.00968	CcSEcCtD
Vandetanib—Pruritus—Metformin—metabolic syndrome X	0.000251	0.00955	CcSEcCtD
Vandetanib—ABCC1—liver—metabolic syndrome X	0.00025	0.00271	CbGeAlD
Vandetanib—Diarrhoea—Metformin—metabolic syndrome X	0.000243	0.00923	CcSEcCtD
Vandetanib—Dizziness—Metformin—metabolic syndrome X	0.000235	0.00892	CcSEcCtD
Vandetanib—CYP3A4—kidney—metabolic syndrome X	0.000228	0.00247	CbGeAlD
Vandetanib—Vomiting—Metformin—metabolic syndrome X	0.000226	0.00858	CcSEcCtD
Vandetanib—Rash—Metformin—metabolic syndrome X	0.000224	0.00851	CcSEcCtD
Vandetanib—Dermatitis—Metformin—metabolic syndrome X	0.000224	0.0085	CcSEcCtD
Vandetanib—Headache—Metformin—metabolic syndrome X	0.000223	0.00845	CcSEcCtD
Vandetanib—Nausea—Metformin—metabolic syndrome X	0.000211	0.00801	CcSEcCtD
Vandetanib—ABCG2—liver—metabolic syndrome X	0.000207	0.00224	CbGeAlD
Vandetanib—CYP3A4—liver—metabolic syndrome X	0.000144	0.00156	CbGeAlD
Vandetanib—FYN—Signaling Pathways—APOE—metabolic syndrome X	5.23e-06	3.32e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—LEP—metabolic syndrome X	5.23e-06	3.32e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—LPL—metabolic syndrome X	5.2e-06	3.29e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—IL6—metabolic syndrome X	5.19e-06	3.29e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—APOA1—metabolic syndrome X	5.17e-06	3.28e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AGT—metabolic syndrome X	5.15e-06	3.26e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—FABP4—metabolic syndrome X	5.13e-06	3.25e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—AKT1—metabolic syndrome X	5.13e-06	3.25e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NOS3—metabolic syndrome X	5.13e-06	3.25e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTGS2—metabolic syndrome X	5.12e-06	3.24e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL6—metabolic syndrome X	5.11e-06	3.24e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL6—metabolic syndrome X	5.11e-06	3.24e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL6—metabolic syndrome X	5.1e-06	3.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—IL6—metabolic syndrome X	5.07e-06	3.22e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—SERPINE1—metabolic syndrome X	5.06e-06	3.21e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—APOE—metabolic syndrome X	5.05e-06	3.2e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PPARG—metabolic syndrome X	5e-06	3.17e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—APOA1—metabolic syndrome X	4.99e-06	3.16e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—AKT1—metabolic syndrome X	4.96e-06	3.15e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF2—metabolic syndrome X	4.96e-06	3.15e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IRS1—metabolic syndrome X	4.91e-06	3.11e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—AKT1—metabolic syndrome X	4.91e-06	3.11e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—INS—metabolic syndrome X	4.9e-06	3.11e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—SERPINE1—metabolic syndrome X	4.88e-06	3.09e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HSD11B1—metabolic syndrome X	4.87e-06	3.08e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—AKT1—metabolic syndrome X	4.86e-06	3.08e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IRS1—metabolic syndrome X	4.84e-06	3.07e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—AKT1—metabolic syndrome X	4.84e-06	3.07e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NOS3—metabolic syndrome X	4.84e-06	3.06e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOB—metabolic syndrome X	4.82e-06	3.05e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	4.79e-06	3.04e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—AKT1—metabolic syndrome X	4.78e-06	3.03e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—AKT1—metabolic syndrome X	4.77e-06	3.02e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IRS1—metabolic syndrome X	4.74e-06	3e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ABCA1—metabolic syndrome X	4.73e-06	3e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—SLC2A4—metabolic syndrome X	4.73e-06	3e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—AKT1—metabolic syndrome X	4.72e-06	2.99e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—AKT1—metabolic syndrome X	4.72e-06	2.99e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL5—metabolic syndrome X	4.7e-06	2.98e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—INS—metabolic syndrome X	4.7e-06	2.98e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—AKT1—metabolic syndrome X	4.7e-06	2.98e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—metabolic syndrome X	4.69e-06	2.97e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL6—metabolic syndrome X	4.69e-06	2.97e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PLA2G4A—metabolic syndrome X	4.69e-06	2.97e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—AKT1—metabolic syndrome X	4.68e-06	2.97e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IRS1—metabolic syndrome X	4.67e-06	2.96e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—AKT1—metabolic syndrome X	4.67e-06	2.96e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NOS3—metabolic syndrome X	4.66e-06	2.95e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—INS—metabolic syndrome X	4.64e-06	2.94e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AGT—metabolic syndrome X	4.61e-06	2.92e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LPL—metabolic syndrome X	4.6e-06	2.92e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—AKT1—metabolic syndrome X	4.59e-06	2.91e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GGT1—metabolic syndrome X	4.59e-06	2.91e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GOT1—metabolic syndrome X	4.59e-06	2.91e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCL2—metabolic syndrome X	4.56e-06	2.89e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TGFB1—metabolic syndrome X	4.56e-06	2.89e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—INS—metabolic syndrome X	4.54e-06	2.88e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—LEP—metabolic syndrome X	4.52e-06	2.86e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—APOE—metabolic syndrome X	4.52e-06	2.86e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ALB—metabolic syndrome X	4.49e-06	2.85e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF1—metabolic syndrome X	4.49e-06	2.84e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IL6—metabolic syndrome X	4.48e-06	2.84e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—INS—metabolic syndrome X	4.47e-06	2.83e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—APOA1—metabolic syndrome X	4.47e-06	2.83e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCL2—metabolic syndrome X	4.47e-06	2.83e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AGT—metabolic syndrome X	4.45e-06	2.82e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—AKT1—metabolic syndrome X	4.42e-06	2.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—metabolic syndrome X	4.42e-06	2.8e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCL2—metabolic syndrome X	4.4e-06	2.79e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PPARG—metabolic syndrome X	4.4e-06	2.79e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF1—metabolic syndrome X	4.39e-06	2.78e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—LEP—metabolic syndrome X	4.36e-06	2.76e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—APOE—metabolic syndrome X	4.36e-06	2.76e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—G6PD—metabolic syndrome X	4.34e-06	2.75e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—IL6—metabolic syndrome X	4.33e-06	2.74e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—IL6—metabolic syndrome X	4.33e-06	2.74e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—AKT1—metabolic syndrome X	4.32e-06	2.74e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF1—metabolic syndrome X	4.32e-06	2.74e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—SERPINE1—metabolic syndrome X	4.32e-06	2.74e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IL6—metabolic syndrome X	4.32e-06	2.74e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—INS—metabolic syndrome X	4.31e-06	2.73e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—APOA1—metabolic syndrome X	4.31e-06	2.73e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—NOS3—metabolic syndrome X	4.3e-06	2.72e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—metabolic syndrome X	4.26e-06	2.7e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SERPINE1—metabolic syndrome X	4.26e-06	2.7e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—AKT1—metabolic syndrome X	4.26e-06	2.7e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HDAC3—metabolic syndrome X	4.23e-06	2.68e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TGFB1—metabolic syndrome X	4.17e-06	2.64e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SERPINE1—metabolic syndrome X	4.17e-06	2.64e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCKR—metabolic syndrome X	4.14e-06	2.62e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPA—metabolic syndrome X	4.14e-06	2.62e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—AKT1—metabolic syndrome X	4.13e-06	2.62e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS3—metabolic syndrome X	4.13e-06	2.61e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—metabolic syndrome X	4.11e-06	2.61e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SERPINE1—metabolic syndrome X	4.11e-06	2.6e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NOS3—metabolic syndrome X	4.07e-06	2.58e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TGFB1—metabolic syndrome X	4.07e-06	2.58e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IRS1—metabolic syndrome X	4.03e-06	2.56e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TGFB1—metabolic syndrome X	4.02e-06	2.55e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLA2G6—metabolic syndrome X	4.01e-06	2.54e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—metabolic syndrome X	3.99e-06	2.53e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—metabolic syndrome X	3.99e-06	2.53e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—metabolic syndrome X	3.98e-06	2.52e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NOS3—metabolic syndrome X	3.98e-06	2.52e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—metabolic syndrome X	3.97e-06	2.52e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOA5—metabolic syndrome X	3.97e-06	2.51e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ALB—metabolic syndrome X	3.95e-06	2.51e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGT—metabolic syndrome X	3.94e-06	2.49e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—metabolic syndrome X	3.93e-06	2.49e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NOS3—metabolic syndrome X	3.92e-06	2.48e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—metabolic syndrome X	3.92e-06	2.48e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOB—metabolic syndrome X	3.89e-06	2.47e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IRS1—metabolic syndrome X	3.89e-06	2.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—INS—metabolic syndrome X	3.86e-06	2.45e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LEP—metabolic syndrome X	3.86e-06	2.44e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOE—metabolic syndrome X	3.86e-06	2.44e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TGFB1—metabolic syndrome X	3.84e-06	2.43e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—metabolic syndrome X	3.83e-06	2.42e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—metabolic syndrome X	3.82e-06	2.42e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOA1—metabolic syndrome X	3.81e-06	2.42e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TGFB1—metabolic syndrome X	3.8e-06	2.41e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL2—metabolic syndrome X	3.8e-06	2.41e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—metabolic syndrome X	3.8e-06	2.41e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PLA2G4A—metabolic syndrome X	3.78e-06	2.4e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—NOS3—metabolic syndrome X	3.78e-06	2.4e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—metabolic syndrome X	3.77e-06	2.39e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1—metabolic syndrome X	3.73e-06	2.37e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—INS—metabolic syndrome X	3.72e-06	2.36e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—LPL—metabolic syndrome X	3.71e-06	2.35e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TGFB1—metabolic syndrome X	3.7e-06	2.35e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TRIB3—metabolic syndrome X	3.69e-06	2.34e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL2—metabolic syndrome X	3.66e-06	2.32e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—metabolic syndrome X	3.66e-06	2.32e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1—metabolic syndrome X	3.6e-06	2.28e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SERPINE1—metabolic syndrome X	3.55e-06	2.25e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—metabolic syndrome X	3.53e-06	2.24e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CD36—metabolic syndrome X	3.53e-06	2.24e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—metabolic syndrome X	3.53e-06	2.24e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—metabolic syndrome X	3.46e-06	2.19e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IRS1—metabolic syndrome X	3.44e-06	2.18e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—metabolic syndrome X	3.44e-06	2.18e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SERPINE1—metabolic syndrome X	3.42e-06	2.17e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—metabolic syndrome X	3.39e-06	2.15e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—metabolic syndrome X	3.39e-06	2.15e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—metabolic syndrome X	3.39e-06	2.15e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NAMPT—metabolic syndrome X	3.31e-06	2.1e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—INS—metabolic syndrome X	3.29e-06	2.09e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCK—metabolic syndrome X	3.29e-06	2.08e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LIPC—metabolic syndrome X	3.29e-06	2.08e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARA—metabolic syndrome X	3.28e-06	2.08e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOC3—metabolic syndrome X	3.27e-06	2.07e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—metabolic syndrome X	3.26e-06	2.07e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL2—metabolic syndrome X	3.24e-06	2.05e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—metabolic syndrome X	3.2e-06	2.03e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—metabolic syndrome X	3.19e-06	2.02e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGT—metabolic syndrome X	3.18e-06	2.01e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—metabolic syndrome X	3.17e-06	2.01e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CETP—metabolic syndrome X	3.17e-06	2.01e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—metabolic syndrome X	3.14e-06	1.99e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—metabolic syndrome X	3.13e-06	1.99e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—metabolic syndrome X	3.11e-06	1.97e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—metabolic syndrome X	3.08e-06	1.95e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOA1—metabolic syndrome X	3.08e-06	1.95e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—metabolic syndrome X	3.07e-06	1.94e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—metabolic syndrome X	3.06e-06	1.94e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—metabolic syndrome X	3.05e-06	1.94e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SCARB1—metabolic syndrome X	3.04e-06	1.92e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—metabolic syndrome X	3.03e-06	1.92e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—metabolic syndrome X	3.03e-06	1.92e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—metabolic syndrome X	3.02e-06	1.91e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SREBF1—metabolic syndrome X	2.95e-06	1.87e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—metabolic syndrome X	2.9e-06	1.84e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—metabolic syndrome X	2.89e-06	1.83e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—metabolic syndrome X	2.89e-06	1.83e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—metabolic syndrome X	2.89e-06	1.83e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMGCR—metabolic syndrome X	2.87e-06	1.82e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT2—metabolic syndrome X	2.87e-06	1.82e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—metabolic syndrome X	2.86e-06	1.81e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—metabolic syndrome X	2.83e-06	1.79e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—metabolic syndrome X	2.83e-06	1.79e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—metabolic syndrome X	2.82e-06	1.79e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—metabolic syndrome X	2.8e-06	1.77e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—metabolic syndrome X	2.79e-06	1.77e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—metabolic syndrome X	2.79e-06	1.77e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—metabolic syndrome X	2.75e-06	1.75e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—metabolic syndrome X	2.73e-06	1.73e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—metabolic syndrome X	2.71e-06	1.72e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—metabolic syndrome X	2.69e-06	1.7e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—metabolic syndrome X	2.67e-06	1.69e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—metabolic syndrome X	2.66e-06	1.69e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—INS—metabolic syndrome X	2.66e-06	1.69e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—metabolic syndrome X	2.64e-06	1.68e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—metabolic syndrome X	2.63e-06	1.67e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—metabolic syndrome X	2.63e-06	1.67e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—metabolic syndrome X	2.61e-06	1.65e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—metabolic syndrome X	2.59e-06	1.64e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—metabolic syndrome X	2.57e-06	1.63e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—metabolic syndrome X	2.56e-06	1.62e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A4—metabolic syndrome X	2.56e-06	1.62e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCA1—metabolic syndrome X	2.56e-06	1.62e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—metabolic syndrome X	2.54e-06	1.61e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—metabolic syndrome X	2.51e-06	1.59e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GGT1—metabolic syndrome X	2.48e-06	1.57e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT1—metabolic syndrome X	2.48e-06	1.57e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—metabolic syndrome X	2.45e-06	1.56e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—metabolic syndrome X	2.41e-06	1.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—metabolic syndrome X	2.41e-06	1.53e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—metabolic syndrome X	2.36e-06	1.49e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—metabolic syndrome X	2.33e-06	1.48e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—metabolic syndrome X	2.32e-06	1.47e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—metabolic syndrome X	2.32e-06	1.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—metabolic syndrome X	2.24e-06	1.42e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—metabolic syndrome X	2.23e-06	1.41e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—metabolic syndrome X	2.22e-06	1.41e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—metabolic syndrome X	2.16e-06	1.37e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—metabolic syndrome X	2.14e-06	1.36e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—metabolic syndrome X	2.13e-06	1.35e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOB—metabolic syndrome X	2.1e-06	1.33e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—metabolic syndrome X	2.06e-06	1.3e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—metabolic syndrome X	2.05e-06	1.3e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLA2G4A—metabolic syndrome X	2.04e-06	1.29e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—metabolic syndrome X	2.03e-06	1.28e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPL—metabolic syndrome X	2.01e-06	1.27e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—metabolic syndrome X	1.98e-06	1.26e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—metabolic syndrome X	1.98e-06	1.25e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—metabolic syndrome X	1.95e-06	1.24e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—metabolic syndrome X	1.91e-06	1.21e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD36—metabolic syndrome X	1.91e-06	1.21e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—metabolic syndrome X	1.9e-06	1.2e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—metabolic syndrome X	1.87e-06	1.18e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—metabolic syndrome X	1.83e-06	1.16e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—metabolic syndrome X	1.8e-06	1.14e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARA—metabolic syndrome X	1.77e-06	1.12e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—metabolic syndrome X	1.74e-06	1.1e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGT—metabolic syndrome X	1.72e-06	1.09e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—metabolic syndrome X	1.69e-06	1.07e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—metabolic syndrome X	1.68e-06	1.07e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOA1—metabolic syndrome X	1.66e-06	1.05e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—metabolic syndrome X	1.63e-06	1.03e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—metabolic syndrome X	1.56e-06	9.87e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—metabolic syndrome X	1.5e-06	9.51e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—metabolic syndrome X	1.46e-06	9.28e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—metabolic syndrome X	1.44e-06	9.12e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—INS—metabolic syndrome X	1.44e-06	9.1e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—metabolic syndrome X	1.33e-06	8.42e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—metabolic syndrome X	1.32e-06	8.34e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—metabolic syndrome X	1.26e-06	7.98e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—metabolic syndrome X	1.15e-06	7.3e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—metabolic syndrome X	1.07e-06	6.8e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—metabolic syndrome X	5.79e-07	3.67e-06	CbGpPWpGaD
